ERBB2 and breast cancer: Considering the different resistance mechanisms that are mediated by the HR/HER2 crosstalk for AIs and TAM, one could argue that there might be clinically significant differences on the efficacy of AIs and TAM, respectively, depending on the treatment sequence in HER2 + BC.